Suraj Muley

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

Ivo N. van Schaik, Vera Bril, Nan van Geloven et al. · The Lancet Neurology · 2017 · 269 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +11

The Quantitative Evaluation of Functional Neuroimaging Experiments: The NPAIRS Data Analysis Framework

Stephen C. Strother, Lars Kai Hansen, Ulrik Kjems et al. · NeuroImage · 2002 · 253 citations

Life Sciences, Biostatistics, Neuroscience +12

The quantitative evaluation of functional neuroimaging experiments: The NPAIRS data analysis framework

Stephen C. Strother, Jon Anderson, Sally A. Frutiger et al. · NeuroImage · 2000 · 225 citations

Life Sciences, Biostatistics, Neuroscience +12

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial

Gil I. Wolfe, Henry J. Kaminski, Inmaculada Aban et al. · The Lancet Neurology · 2019 · 223 citations · Full text

Medicine, Endocrinology, Surgery +5